Young G, Sidonio RF, Liesner R, et al. HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors. ASH 59th Annual Meeting & Exhibition, abstract 85.
Risico’s en voordelen van DOAC’s versus warfarine
sep 2018 | Benigne hematologie